Diet and Exercise in Cystic Fibrosis - 1st Edition - ISBN: 9780128000519, 9780128005880

Diet and Exercise in Cystic Fibrosis

1st Edition

Editors: Ronald Ross Watson
eBook ISBN: 9780128005880
Hardcover ISBN: 9780128000519
Imprint: Academic Press
Published Date: 12th August 2014
Page Count: 396
Tax/VAT will be calculated at check-out Price includes VAT (GST)
30% off
30% off
30% off
30% off
30% off
20% off
20% off
30% off
30% off
30% off
30% off
30% off
20% off
20% off
30% off
30% off
30% off
30% off
30% off
20% off
20% off
106.00
74.20
74.20
74.20
74.20
74.20
84.80
84.80
85.00
59.50
59.50
59.50
59.50
59.50
68.00
68.00
140.00
98.00
98.00
98.00
98.00
98.00
112.00
112.00
Unavailable
Price includes VAT (GST)
× DRM-Free

Easy - Download and start reading immediately. There’s no activation process to access eBooks; all eBooks are fully searchable, and enabled for copying, pasting, and printing.

Flexible - Read on multiple operating systems and devices. Easily read eBooks on smart phones, computers, or any eBook readers, including Kindle.

Open - Buy once, receive and download all available eBook formats, including PDF, EPUB, and Mobi (for Kindle).

Institutional Access

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Description

Diet and Exercise in Cystic Fibrosis, a unique reference edited by distinguished and internationally recognized nutritionist and immunologist Ronald Ross Watson, fills the gap in the current dietary modalities aimed at controlling cystic fibrosis.  Using expert evaluation on the latest studies of the role of food and exercise in lifelong management of cystic fibrosis, this valuable resource shows how to maintain intestinal, hepatic, and pulmonary high quality function for improving quality of life for those with cystic fibrosis. A helpful tool for researchers and clinicians alike, this reference helps refine research targets, and provides the beginning of a structured dietary management scheme for those with cystic fibrosis.

Key Features

  • Provides a detailed resource that reviews the health problems occurring in Cystic Fibrosis relative to dietary, complementary, and alternative therapies
  • Contains expert evaluation on the role of foods and exercise for lifelong management of Cystic Fibrosis to maintain intestinal, hepatic, and pulmonary high quality function for improved quality of life
  • Defines and evaluates various nutritional and dietary approaches to the unique problems of those with Cystic Fibrosis

Readership

Respiratory / Pulmonary Researchers and Clinicians

Table of Contents

  • Dedication
  • Preface
  • Acknowledgments
  • Biography
  • List of Contributors
  • Section A. Overview of Nutrition and Diets in Cystic Fibrosis
    • Chapter 1. Nutrition for Pregnant Women Who Have Cystic Fibrosis
      • 1.1. Introduction
      • 1.2. Historical Perspective
      • 1.3. Nutrition: Review of the Literature
      • 1.4. Clinical Guidance
      • 1.5. Conclusion
    • Chapter 2. Disordered Eating and Body Image in Cystic Fibrosis
      • 2.1. Introduction
      • 2.2. Quality of Life
      • 2.3. Body Image
      • 2.4. Eating Behaviors
      • 2.5. Body Dissatisfaction and Disordered Eating: Identification, Treatment, and Intervention Strategies
      • 2.6. Conclusion
    • Chapter 3. Neonatal Screening and Nutrition/Growth in Cystic Fibrosis: A Review
      • 3.1. Introduction
      • 3.2. Review of the Literature
      • 3.3. RCTs Studies
      • 3.4. Studies Using CF Registry Data
      • 3.5. Cohort Observational Studies
      • 3.6. Discussion
    • Chapter 4. Cystic Fibrosis Nutrition: Outcomes, Treatment Guidelines, and Risk Classification
      • 4.1. Nutrition and Outcomes
      • 4.2. Assessing Weight Change and Growth in CF
      • 4.3. Energy Guidelines
      • 4.4. Vitamins and Minerals
      • 4.5. Malabsorption
      • 4.6. Increasing Intake
      • 4.7. Comorbid Diseases/Complications That Affect Nutrition
      • 4.8. Nutrition Screening and Risk Classification in a Clinical Setting
    • Chapter 5. Clinic, Nutrition, and Spirometry in Cystic Fibrosis
      • 5.1. Introduction
      • 5.2. Clinical Characteristics
      • 5.3. Methods of Assessing Growth and Pulmonary Function
      • 5.4. Factors that Interfere with the Growth of CF Patients
      • 5.5. Metabolic Process in Cystic Fibrosis: High Calorie Consumption
      • 5.6. Metabolic and Nutritional Secondary Processes
      • 5.7. Relationship between Endocrine-Metabolic Diseases and Lung Development
      • 5.8. Nutrition and Lung Function
      • 5.9. Conclusion
    • Chapter 6. Family Mealtimes and Children with Cystic Fibrosis
      • Conclusion and Future Directions
    • Chapter 7. Disturbed Sleep Behaviors and Melatonin in Sleep Dysfunction and Treatment of Cystic Fibrosis
      • 7.1. Introduction
      • 7.2. Sleep Dysfunction in Cystic Fibrosis
      • 7.3. Melatonin and CF
      • 7.4. Conclusion
    • Chapter 8. Age at Diagnosis and Disease Progression of Cystic Fibrosis
      • 8.1. Age at Diagnosis of CF
      • 8.2. Morbidity at Diagnosis and Introduction to Morbidity
      • 8.3. Nutritional Morbidity
      • 8.4. Lung Morbidity
      • 8.5. Liver Morbidity
      • 8.6. Overall Morbidity
      • 8.7. Discussion
    • Chapter 9. The Effects of Caffeine, Alcohol, and Tobacco in Cystic Fibrosis
      • 9.1. Introduction
      • 9.2. Cystic Fibrosis Overview
      • 9.3. Caffeine and Patients with CF
      • 9.4. Alcohol and Patients with CF
      • 9.5. Tobacco and Patients with CF
      • 9.6. Summary
    • Chapter 10. Eating Disorders and Disturbed Eating Attitudes and Behaviors Typical in CF
      • 10.1. Poor Nutritional Status in CF
      • 10.2. Evidence of EDs in CF
      • 10.3. Disturbed Eating Attitudes and Behaviors in CF
      • 10.4. Measures of DEABs for the CF Population
      • 10.5. Conclusion
  • Section B. Vitamin D Deficiency and Supplementation in Growth and Health in Children with Cystic Fibrosis
    • Chapter 11. Vitamin D Bioavailability in Cystic Fibrosis
      • 11.1. Introduction
      • 11.2. Vitamin D Status in Cystic Fibrosis
      • 11.3. Photosynthesis of Vitamin D3
      • 11.4. Vitamin D Digestion and Absorption
      • 11.5. Vitamin D Storage
      • 11.6. Vitamin D Transport
      • 11.7. VITAMIN D Metabolism
      • 11.8. Vitamin D Excretion
      • 11.9. Vitamin D Action
      • 11.10. Importance of Vitamin D for Cystic Fibrosis Patients
      • 11.11. Conclusion and Future Directions
    • Chapter 12. Vitamin D in Cystic Fibrosis
      • 12.1. Introduction
      • 12.2. Prevalence of Deficiency in CF
      • 12.3. Impact of Vitamin D Deficiency in CF
      • 12.4. Vitamin D Treatments in CF
      • 12.5. Conclusion
    • Chapter 13. Specialty Foods for Children with Cystic Fibrosis
      • 13.1. Cystic Fibrosis
      • 13.2. Nutritional and Growth Problems Associated with Cystic Fibrosis
      • 13.3. Cystic Fibrosis-Related Diabetes Mellitus
      • 13.4. Specialty Foods and Diets
      • 13.5. Conclusion
    • Chapter 14. Fat-Soluble Vitamin Deficiency in Cystic Fibrosis
      • 14.1. Introduction
      • 14.2. CF Genetics
      • 14.3. Signs and Symptoms
      • 14.4. Nutrition Overview for CF
      • 14.5. Fat-Soluble Vitamins
      • 14.6. Vitamin A Deficiency
      • 14.7. Vitamin E Deficiency
      • 14.8. Vitamin K Deficiency
      • 14.9. Vitamin D Deficiency
      • 14.10. Treatment and Therapy
      • 14.11. CF and Vitamin Supplementation
    • Chapter 15. Can Light Provide a Vitamin D Supplement in Cystic Fibrosis?
      • 15.1. Introduction
      • 15.2. Vitamin D Deficiency in CF
      • 15.3. Prevention and Treatment of Vitamin D Deficiency in CF
      • 15.4. Ultraviolet B Radiation in the Management of Vitamin D Deficiency in CF
      • 15.5. Conclusion
    • Chapter 16. Pediatric Cystic Fibrosis and Fat-Soluble Vitamins
      • 16.1. Introduction
      • 16.2. Vitamin A
      • 16.3. Vitamin D
      • 16.4. Vitamin E
      • 16.5. Vitamin K
      • 16.6. Conclusion
  • Section C. Vitamin Deficiency, Antioxidants, and Supplementation in Cystic Fibrosis Patients
    • Chapter 17. Vitamin Supplements: A Role in Cystic Fibrosis Patients?
      • 17.1. Introduction
      • 17.2. Vitamin A
      • 17.3. Vitamin D
      • 17.4. Vitamin E
      • 17.5. Vitamin K
      • 17.6. Water-Soluble Vitamins
    • Chapter 18. Nutritional Strategies to Modulate Inflammation and Oxidative Stress in Patients with Cystic Fibrosis
      • 18.1. Oxidative Stress and Inflammation in Cystic Fibrosis
      • 18.2. Antioxidant Deficiencies in CF
      • 18.3. Dietary Interventions in CF
    • Chapter 19. Vitamin A Supplementation Therapy for Patients with Cystic Fibrosis
      • 19.1. Overview of Vitamin A
      • 19.2. Biological Profile of Vitamin A in Cystic Fibrosis
      • 19.3. Effectiveness of Vitamin A Treatments in Preventing Negative Symptoms
    • Chapter 20. The Emergence of Polyphenols in the Potentiation of Treatment Modality in Cystic Fibrosis
      • 20.1. Introduction
      • 20.2. Role of polyphenols in Other Diseases and Possibly CF
      • 20.3. Therapeutic Capacity of polyphenols to CFTR Function
      • 20.4. Antimicrobial Capacity of polyphenols
      • 20.5. Anti-inflammatory Properties of polyphenols
      • 20.6. Role of polyphenols in CFTR-related Comorbidities
      • 20.7. CF-Related mental Impairments
      • 20.8. Conclusion
    • Chapter 21. Chronic Infection with Pseudomonas aeruginosa in an Animal Model of Oxidative Stress: Lessons for Patients with Cystic Fibrosis
      • 21.1. Oxidative Stress in CF
      • 21.2. Animal Models of Chronic Lung Infection
      • 21.3. Chronic Lung Infection in Animal Model of Oxidative Stress
      • 21.4. Lessons for CF Patients
    • Chapter 22. Vitamin K in Cystic Fibrosis
      • 22.1. Vitamin K Supplementation for Cystic Fibrosis
    • Chapter 23. Vitamin K and Cystic Fibrosis
      • 23.1. Introduction
      • 23.2. Dietary Sources
      • 23.3. Vitamin K Digestion
      • 23.4. Biochemistry
      • 23.5. Vitamin K and CF
      • 23.6. Diagnosis of Vitamin K Deficiency
      • 23.7. Vitamin K Preparations
      • 23.8. Vitamin K Supplementation in CF
      • 23.9. Treatment of Vitamin K Deficiency
      • 23.10. Summary
  • Section D. Management of Diabetes and Celiac Disease Associated with Cystic Fibrosis: Role of Nutrition and Food
    • Chapter 24. Insulin, Body Mass, and Growth in Young Cystic Fibrosis Patients
      • 24.1. Insulin Secretion—Normal Physiology
      • 24.2. Progressive Insulin Deficiency Is a Feature of CF
      • 24.3. Normal Physiology of Insulin-Mediated Glucose Uptake
      • 24.4. Implications of Insulin Deficiency on Airway Glucose and Bacterial Colonization
      • 24.5. Normal Physiology of Insulin Action on Growth and Anabolism
      • 24.6. Implications of Insulin Deficiency on Growth in CF
      • 24.7. Summary of Importance of Adequate Insulin Secretion in Cystic Fibrosis
      • 24.8. Current Management Principles of Insulin Therapy in Cystic Fibrosis
      • 24.9. Future Directions of Insulin Therapies
    • Chapter 25. Low Glycemic Index Dietary Interventions in Cystic Fibrosis
      • 25.1. Introduction
      • 25.2. Evidence for Effect in Non-CF Populations with Diabetes
      • 25.3. Evidence for the Use of a Low GI Diet in CF
      • 25.4. Practical Considerations of a Low GI Dietary Intervention in CF
      • 25.5. Theoretical Applications of a Low GI Dietary Intervention in CF
      • 25.6. Conclusions
    • Chapter 26. Insulin Resistance in Cystic Fibrosis: Management
      • 26.1. Insulin Resistance in Cystic Fibrosis: An Overview
      • 26.2. Pathophysiology of Insulin Resistance
      • 26.3. Management of Insulin Resistance
    • Chapter 27. Cystic Fibrosis and Celiac Disease
      • 27.1. Introduction
      • 27.2. Clinical Features
      • 27.3. Testing
      • 27.4. Treatment
      • 27.5. Relation to Cystic Fibrosis
      • 27.6. Conclusion
  • Section E. Nutrition and Pulmonary Function in Cystic Fibrosis Patients
    • Chapter 28. Probiotic Supplementation and Pulmonary Exacerbations in Patients with Cystic Fibrosis
      • 28.1. Intestinal Inflammation
      • 28.2. Probiotics
      • 28.3. Summary
    • Chapter 29. Buteyko: Better Breathing = Better Health
      • 29.1. Introduction
      • 29.2. Breathing
      • 29.3. The Buteyko Method
      • 29.4. Conclusion
    • Chapter 30. Lactoferrin and Cystic Fibrosis Airway Infection
      • 30.1. Introduction
      • 30.2. Iron Homeostasis in Healthy and CF Airways
      • 30.3. CF Airway Infections
      • 30.4. Inflammation in CF Airways
      • 30.5. Antimicrobials of the Human Airway: Lactoferrin, a Component of Innate Immunity
      • 30.6. Lactoferrin and CF Airways
      • 30.7. Future Approaches in the Therapy of CF Airway Infections
      • 30.8. Concluding Remarks
    • Chapter 31. Cystic Fibrosis–Related Diabetes: Lung Function and Nutritional Status
      • 31.1. Introduction
      • 31.2. Cystic Fibrosis–Related Diabetes: Physiopathology
      • 31.3. Cystic Fibrosis–Related Diabetes: Screening and Diagnosis
      • 31.4. Cystic Fibrosis–Related Diabetes: Treatment
      • 31.5. Cystic Fibrosis–Related Diabetes: Comorbidity and Complications
      • 31.6. Perspectives and Conclusions
  • Section F. Exercise and Behavior in Management of Cystic Fibrosis
    • Chapter 32. Exercise Testing in CF, the What and How
      • 32.1. Utility of Exercise Testing
      • 32.2. Exercise Tests
      • 32.3. The Godfrey Protocol
      • 32.4. The Bruce Protocol
      • 32.5. Field Tests
      • 32.6. Conducting an Exercise Test
      • 32.7. Interpreting an Exercise Test
    • Chapter 33. Mechanisms of Exercise Limitation in Cystic Fibrosis: A Literature Update of Involved Mechanisms
      • 33.1. Introduction
      • 33.2. Methods
      • 33.3. Results
      • 33.4. Ventilatory Parameters
      • 33.5. Muscle Function
      • 33.6. Cardiac Constraints
      • 33.7. Concluding Remarks
      • 33.8. Clinical Implications
    • Chapter 34. Physical Activity Assessment and Impact
      • 34.1. Introduction
      • 34.2. Tools for Measuring Physical Activity
      • 34.3. Normative Data for Physical Activity in CF
      • 34.4. Methods of Analyzing and Reporting Physical Activity Data
      • 34.5. Evidence for Impact of Physical Activity on Health of Patients with CF
      • 34.6. Discussion
    • Chapter 35. Motivating Physical Activity: Skills and Strategies for Behavior Change
      • 35.1. Beyond a Prescription
      • 35.2. A’s of Physical Activity Counseling: A Framework for Behavior Change
      • 35.3. Physical Activity Resources for Patients and Practitioners
    • Chapter 36. Diet, Food, Nutrition, and Exercise in Cystic Fibrosis
      • 36.1. Nutrition Considerations for Exercise
      • 36.2. Hydration Considerations for Exercise
    • Chapter 37. Personalizing Exercise and Physical Activity Prescriptions
      • 37.1. Introduction
      • 37.2. Components of a Comprehensive Exercise Prescription
      • 37.3. Individualizing Physical Activity and Exercise Prescription for the Adult with Cystic Fibrosis
      • 37.4. Individualizing Physical Activity and Exercise Prescription in the Child with Cystic Fibrosis
  • Section G. FAT and LIPID Metabolism in Cystic Fibrosis
    • Chapter 38. The Pancreatic Duct Ligated Pig as a Model for Patients Suffering from Exocrine Pancreatic Insufficiency—Studies of Vitamin A and E Status
      • 38.1. Introduction
      • 38.2. Advantages of an Animal Model to Study Effects of EPI on Vitamin Status
      • 38.3. Effects of EPI on Serum α-Tocopherol Concentrations in Adult Minipigs, Study 1
      • 38.4. Effects of EPI on Retinol and α-Tocopherol Concentrations in Serum and Liver Tissue of Juvenile Pigs, Study 2
      • 38.5. Discussion
    • Chapter 39. Unsaturated Fatty Acids in Cystic Fibrosis: Metabolism and Therapy
      • 39.1. Introduction
      • 39.2. Patterns of Polyunsaturated FA Alterations in CF
      • 39.3. Relationship between FA Alterations and Clinical Features of CF
      • 39.4. Mechanisms of Altered FA Metabolism in CF
      • 39.5. Dietary and Therapeutic Implications of FA Metabolism in CF
      • 39.6. Conclusions
    • Chapter 40. Essential Fatty Acid Deficiency in Cystic Fibrosis: Malabsorption or Metabolic Abnormality?
      • 40.1. Introduction
      • 40.2. Essential Fatty Acids
      • 40.3. Fatty Acids in Cystic Fibrosis
      • 40.4. Issues on Obesity and How to Intervene
      • 40.5. Conclusions
    • Chapter 41. Persistent Fat Malabsorption in Cystic Fibrosis
      • 41.1. Introduction
      • 41.2. Physiology of Intestinal Dietary Fat Absorption
      • 41.3. Impaired Intestinal Dietary Fat Absorption in Cystic Fibrosis
      • 41.4. Intestinal pH and Bicarbonate Secretion
      • 41.5. Intraluminal Bile Salts
      • 41.6. Intestinal Mucosal Abnormalities
      • 41.7. Small Intestinal Bacterial Overgrowth
      • 41.8. Small Intestinal Transit Time
      • 41.9. Conclusion
    • Chapter 42. Omega-3 Fatty Acids and Cystic Fibrosis
      • 42.1. Introduction
      • 42.2. Omega-3 Fatty Acid: A Role in Cystic Fibrosis?
      • 42.3. Omega Fatty Acids and CF: Animal Models
      • 42.4. Omega Fatty Acids and CF: Clinical Trials
      • 42.5. Conclusion
  • Index

Details

No. of pages:
396
Language:
English
Copyright:
© Academic Press 2015
Published:
Imprint:
Academic Press
eBook ISBN:
9780128005880
Hardcover ISBN:
9780128000519

About the Editor

Ronald Ross Watson

Ronald Ross Watson

Ronald Ross Watson PhD is a professor of Health Promotion Sciences in the University of Arizona Mel and Enid Zuckerman College of Public Health. He was one of the founding members of this school serving the mountain west of the USA. He is a professor of Family and Community Medicine in the School of Medicine at the University of Arizona. He began his research in public health at the Harvard School of Public Health as a fellow in 1971 doing field work on vaccines in Saudi Arabia. He has done clinical studies in Colombia, Iran, Egypt, Saudi Arabia, and USA which provides a broad international view of public health. He has served in the military reserve hospital for 17 years with extensive training in medical responses to disasters as the chief biochemistry officer of a general hospital, retiring at a Lt. Colonel. He published 450 papers, and presently directs or has directed several NIH funded biomedical grants relating to alcohol and disease particularly immune function and cardiovascular effects including studying complementary and alternative medicines. Professor Ronald Ross Watson was Director of a National Institutes of Health funded Alcohol Research Center for 5 years. The main goal of the Center was to understand the role of ethanol-induced immunosuppression on immune function and disease resistance in animals. He is an internationally recognized alcohol-researcher, nutritionist and immunologist. He also initiated and directed other NIH-associated work at The University of Arizona, College of Medicine. Dr. Watson has funding from companies and non-profit foundations to study bioactive foods’ components in health promotion. Professor Watson attended the University of Idaho, but graduated from Brigham Young University in Provo, Utah, with a degree in Chemistry in 1966. He completed his Ph.D. degree in 1971 in Biochemistry from Michigan State University. His postdoctoral schooling was completed at the Harvard School of Public Health in Nutrition and Microbiology, including a two-year postdoctoral research experience in immunology. Professor Watson is a distinguished member of several national and international nutrition, immunology, and cancer societies. Overall his career has involved studying many foods for their uses in health promotion. He has edited 120 biomedical reference books, particularly in health and 450 papers and chapters. His teaching and research in foods, nutrition and bacterial disease also prepare him to edit this book. He has 4 edited works on nutrition in aging. He has extensive experience working with natural products, alcohol, exercise, functional foods and dietary extracts for health benefits and safety issues, including getting 12 patents. Dr. Watson has done laboratory studies in mice on immune functions that decline with aging and the role of supplements in delaying this process as modified by alcohol and drugs of abuse.

Affiliations and Expertise

University of Arizona, Mel and Enid Zuckerman College of Public Health, and School of Medicine, Arizona Health Sciences Center, Tucson, AZ, USA